Prediction of Unresectability and Prognosis in Patients Undergoing Surgery on Suspicion of Pancreatic Cancer Using Carbohydrate Antigen 19-9, Interleukin 6, and YKL-40

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Prediction of Unresectability and Prognosis in Patients Undergoing Surgery on Suspicion of Pancreatic Cancer Using Carbohydrate Antigen 19-9, Interleukin 6, and YKL-40. / Palmquist, Camilla; Dehlendorff, Christian; Calatayud, Dan; Hansen, Carsten Palnæs; Hasselby, Jane Preuss; Johansen, Julia Sidenius.

In: Pancreas, Vol. 49, No. 1, 2020, p. 53-61.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Palmquist, C, Dehlendorff, C, Calatayud, D, Hansen, CP, Hasselby, JP & Johansen, JS 2020, 'Prediction of Unresectability and Prognosis in Patients Undergoing Surgery on Suspicion of Pancreatic Cancer Using Carbohydrate Antigen 19-9, Interleukin 6, and YKL-40', Pancreas, vol. 49, no. 1, pp. 53-61. https://doi.org/10.1097/MPA.0000000000001466

APA

Palmquist, C., Dehlendorff, C., Calatayud, D., Hansen, C. P., Hasselby, J. P., & Johansen, J. S. (2020). Prediction of Unresectability and Prognosis in Patients Undergoing Surgery on Suspicion of Pancreatic Cancer Using Carbohydrate Antigen 19-9, Interleukin 6, and YKL-40. Pancreas, 49(1), 53-61. https://doi.org/10.1097/MPA.0000000000001466

Vancouver

Palmquist C, Dehlendorff C, Calatayud D, Hansen CP, Hasselby JP, Johansen JS. Prediction of Unresectability and Prognosis in Patients Undergoing Surgery on Suspicion of Pancreatic Cancer Using Carbohydrate Antigen 19-9, Interleukin 6, and YKL-40. Pancreas. 2020;49(1):53-61. https://doi.org/10.1097/MPA.0000000000001466

Author

Palmquist, Camilla ; Dehlendorff, Christian ; Calatayud, Dan ; Hansen, Carsten Palnæs ; Hasselby, Jane Preuss ; Johansen, Julia Sidenius. / Prediction of Unresectability and Prognosis in Patients Undergoing Surgery on Suspicion of Pancreatic Cancer Using Carbohydrate Antigen 19-9, Interleukin 6, and YKL-40. In: Pancreas. 2020 ; Vol. 49, No. 1. pp. 53-61.

Bibtex

@article{00cdbed9d61a4ff1bb4ecb77398d497b,

title = "Prediction of Unresectability and Prognosis in Patients Undergoing Surgery on Suspicion of Pancreatic Cancer Using Carbohydrate Antigen 19-9, Interleukin 6, and YKL-40",

abstract = "OBJECTIVES: The aim was to determine whether serum levels of carbohydrate antigen (CA) 19-9, interleukin 6 (IL-6), and YKL-40 could identify advanced disease and poor prognosis in pancreatic cancer (PC) patients intraoperatively diagnosed with locally advanced or metastatic disease.METHODS: Two hundred ninety patients were included with preoperative blood samples. Plasma IL-6 and YKL-40 were determined by enzyme-linked immunosorbent assays.RESULTS: Interleukin 6 was elevated in patients with unresectable PC compared with resectable PC (P = 0.03). Carbohydrate antigen 19-9 and YKL-40 were similar. Patients with resectable tumors and greater than median preoperative CA 19-9, IL-6, and YKL-40 had shorter overall survival than patients with low levels (CA 19-9: hazard ratio [HR], 1.79; 95% confidence interval [CI], 1.13-2.83; P = 0.01; IL-6: HR, 1.83; 95% CI, 1.20-2.78; P = 0.01; YKL-40: HR, 1.60; 95% CI, 1.02-2.49; P = 0.04). Patients with resectable tumors and 2 or 3 high biomarker levels had significantly reduced overall survival compared with patients with low levels (2 high: HR, 2.97; 95% CI, 1.44-6.10; P = 0.00; 3 high: HR, 3.10; 95% CI, 1.45-6.65; P = 0.00).CONCLUSIONS: Preoperative levels of CA 19-9, IL-6, and YKL-40 may be useful to identify a subgroup of PC patients with poor prognosis.",

keywords = "Biomarkers, Tumor/blood, CA-19-9 Antigen/blood, Chitinase-3-Like Protein 1/blood, Enzyme-Linked Immunosorbent Assay, Female, Humans, Interleukin-6/blood, Kaplan-Meier Estimate, Male, Middle Aged, Pancreatic Neoplasms/blood, Predictive Value of Tests, Preoperative Period, Prognosis",

author = "Camilla Palmquist and Christian Dehlendorff and Dan Calatayud and Hansen, {Carsten Paln{\ae}s} and Hasselby, {Jane Preuss} and Johansen, {Julia Sidenius}",

year = "2020",

doi = "10.1097/MPA.0000000000001466",

language = "English",

volume = "49",

pages = "53--61",

journal = "Pancreas",

issn = "0885-3177",

publisher = "Lippincott Williams & Wilkins",

number = "1",

}

RIS

TY - JOUR

T1 - Prediction of Unresectability and Prognosis in Patients Undergoing Surgery on Suspicion of Pancreatic Cancer Using Carbohydrate Antigen 19-9, Interleukin 6, and YKL-40

AU - Palmquist, Camilla

AU - Dehlendorff, Christian

AU - Calatayud, Dan

AU - Hansen, Carsten Palnæs

AU - Hasselby, Jane Preuss

AU - Johansen, Julia Sidenius

PY - 2020

Y1 - 2020

N2 - OBJECTIVES: The aim was to determine whether serum levels of carbohydrate antigen (CA) 19-9, interleukin 6 (IL-6), and YKL-40 could identify advanced disease and poor prognosis in pancreatic cancer (PC) patients intraoperatively diagnosed with locally advanced or metastatic disease.METHODS: Two hundred ninety patients were included with preoperative blood samples. Plasma IL-6 and YKL-40 were determined by enzyme-linked immunosorbent assays.RESULTS: Interleukin 6 was elevated in patients with unresectable PC compared with resectable PC (P = 0.03). Carbohydrate antigen 19-9 and YKL-40 were similar. Patients with resectable tumors and greater than median preoperative CA 19-9, IL-6, and YKL-40 had shorter overall survival than patients with low levels (CA 19-9: hazard ratio [HR], 1.79; 95% confidence interval [CI], 1.13-2.83; P = 0.01; IL-6: HR, 1.83; 95% CI, 1.20-2.78; P = 0.01; YKL-40: HR, 1.60; 95% CI, 1.02-2.49; P = 0.04). Patients with resectable tumors and 2 or 3 high biomarker levels had significantly reduced overall survival compared with patients with low levels (2 high: HR, 2.97; 95% CI, 1.44-6.10; P = 0.00; 3 high: HR, 3.10; 95% CI, 1.45-6.65; P = 0.00).CONCLUSIONS: Preoperative levels of CA 19-9, IL-6, and YKL-40 may be useful to identify a subgroup of PC patients with poor prognosis.

AB - OBJECTIVES: The aim was to determine whether serum levels of carbohydrate antigen (CA) 19-9, interleukin 6 (IL-6), and YKL-40 could identify advanced disease and poor prognosis in pancreatic cancer (PC) patients intraoperatively diagnosed with locally advanced or metastatic disease.METHODS: Two hundred ninety patients were included with preoperative blood samples. Plasma IL-6 and YKL-40 were determined by enzyme-linked immunosorbent assays.RESULTS: Interleukin 6 was elevated in patients with unresectable PC compared with resectable PC (P = 0.03). Carbohydrate antigen 19-9 and YKL-40 were similar. Patients with resectable tumors and greater than median preoperative CA 19-9, IL-6, and YKL-40 had shorter overall survival than patients with low levels (CA 19-9: hazard ratio [HR], 1.79; 95% confidence interval [CI], 1.13-2.83; P = 0.01; IL-6: HR, 1.83; 95% CI, 1.20-2.78; P = 0.01; YKL-40: HR, 1.60; 95% CI, 1.02-2.49; P = 0.04). Patients with resectable tumors and 2 or 3 high biomarker levels had significantly reduced overall survival compared with patients with low levels (2 high: HR, 2.97; 95% CI, 1.44-6.10; P = 0.00; 3 high: HR, 3.10; 95% CI, 1.45-6.65; P = 0.00).CONCLUSIONS: Preoperative levels of CA 19-9, IL-6, and YKL-40 may be useful to identify a subgroup of PC patients with poor prognosis.

KW - Biomarkers, Tumor/blood

KW - CA-19-9 Antigen/blood

KW - Chitinase-3-Like Protein 1/blood

KW - Enzyme-Linked Immunosorbent Assay

KW - Female

KW - Humans

KW - Interleukin-6/blood

KW - Kaplan-Meier Estimate

KW - Male

KW - Middle Aged

KW - Pancreatic Neoplasms/blood

KW - Predictive Value of Tests

KW - Preoperative Period

KW - Prognosis

U2 - 10.1097/MPA.0000000000001466

DO - 10.1097/MPA.0000000000001466

M3 - Journal article

C2 - 31856080

VL - 49

SP - 53

EP - 61

JO - Pancreas

JF - Pancreas

SN - 0885-3177

IS - 1

ER -

ID: 256578093